|
1
|
Ezzedine K, Eleftheriadou V, Whitton M and
van Geel N: Vitiligo. Lancet. 386:74–84. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Krüger C and Schallreuter KU: A review of
the worldwide prevalence of vitiligo in children/adolescents and
adults. Int J Dermatol. 51:1206–1212. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gauthier Y, Cario Andre M and Taïeb A: A
critical appraisal of vitiligo etiologic theories. Is melanocyte
loss a melanocytorrhagy? Pigment Cell Res. 16:322–332.
2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
D'Mello SA, Finlay GJ, Baguley BC and
Askarian-Amiri ME: Signaling pathways in melanogenesis. Int J Mol
Sci. 17(1144)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Videira IF, Moura DF and Magina S:
Mechanisms regulating melanogenesis. An Bras Dermatol. 88:76–83.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Costin GE and Hearing VJ: Human skin
pigmentation: Melanocytes modulate skin color in response to
stress. FASEB J. 21:976–994. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hara M, Toyoda M, Yaar M, Bhawan J, Avila
EM, Penner IR and Gilchrest BA: Innervation of melanocytes in human
skin. J Exp Med. 184:1385–1395. 1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ohbayashi N and Fukuda M: Recent advances
in understanding the molecular basis of melanogenesis in
melanocytes. F1000Res 9: F1000 Faculty Rev-608, 2020.
|
|
9
|
Slominski A, Tobin DJ, Shibahara S and
Wortsman J: Melanin pigmentation in mammalian skin and its hormonal
regulation. Physiol Rev. 84:1155–1228. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Slominski A, Zmijewski MA and Pawelek J:
L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators
of melanocyte functions. Pigment Cell Melanoma Res. 25:14–27.
2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iannella G, Greco A, Didona D, Didona B,
Granata G, Manno A, Pasquariello B and Magliulo G: Vitiligo:
Pathogenesis, clinical variants and treatment approaches. Autoimmun
Rev. 15:335–343. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Boniface K, Seneschal J, Picardo M and
Taïeb A: Vitiligo: Focus on clinical aspects, immunopathogenesis,
and therapy. Clin Rev Allergy Immunol. 54:52–67. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kundu RV, Mhlaba JM, Rangel SM and Le
Poole IC: The convergence theory for vitiligo: A reappraisal. Exp
Dermatol. 28:647–655. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Moretti S, Spallanzani A, Amato L,
Hautmann G, Gallerani I and Fabbri P: Vitiligo and epidermal
microenvironment: Possible involvement of keratinocyte-derived
cytokines. Arch Dermatol. 138:273–274. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rodrigues M, Ezzedine K, Hamzavi I, Pandya
AG, Harris JE and Group VW: New discoveries in the pathogenesis and
classification of vitiligo. J Am Acad Dermatol. 77:1–13.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Passeron T: Medical and maintenance
treatments for vitiligo. Dermatol Clin. 35:163–170. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Whitton ME, Pinart M, Batchelor J,
Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V and Ezzedine
K: Interventions for vitiligo. Cochrane Database Syst Rev.
(CD003263)2015.PubMed/NCBI View Article : Google Scholar : doi:
10.1002/14651858.CD003263.pub5.
|
|
18
|
Taieb A, Alomar A, Böhm M, Dell'anna ML,
De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ,
Jouary T, et al: Guidelines for the management of vitiligo: The
European dermatology forum consensus. Br J Dermatol. 168:5–19.
2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gawkrodger DJ, Ormerod AD, Shaw L,
Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K,
Therapy Guidelines and Audit Subcommittee: British Association of
Dermatologists et al. Guideline for the diagnosis and
management of vitiligo. Br J Dermatol. 159:1051–1076.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Njoo MD, Spuls PI, Bos JD, Westerhof W and
Bossuyt PM: Nonsurgical repigmentation therapies in vitiligo.
Meta-analysis of the literature. Arch Dermatol. 134:1532–1540.
1998.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Faria AR, Tarlé RG, Dellatorre G, Mira MT
and Castro CC: Vitiligo-Part 2-classification, histopathology and
treatment. An Bras Dermatol. 89:784–790. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rodrigues M, Ezzedine K, Hamzavi I, Pandya
AG, Harris JE and Group VW: Current and emerging treatments for
vitiligo. J Am Acad Dermatol. 77:17–29. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bleuel R and Eberlein B: Therapeutic
management of vitiligo. J Dtsch Dermatol Ges. 16:1309–1313.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lotti T, Agarwal K, Podder I, Satolli F,
Kassir M, Schwartz RA, Wollina U, Grabbe S, Navarini AA, Mueller SM
and Goldust M: Safety of the current drug treatments for vitiligo.
Expert Opin Drug Saf. 19:499–511. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kwinter J, Pelletier J, Khambalia A and
Pope E: High-potency steroid use in children with vitiligo: A
retrospective study. J Am Acad Dermatol. 56:236–241.
2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ballona R: ‘Soft steroids’ o corticoides
suaves en Dermatología Pediátrica. Dermatol Pediatr Lat. 3:150–157.
2005.
|
|
27
|
Felsten LM, Alikhan A and Petronic-Rosic
V: Vitiligo: A comprehensive overview Part II: Treatment options
and approach to treatment. J Am Acad Dermatol. 65:493–514.
2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lee JH, Kwon HS, Jung HM, Lee H, Kim GM,
Yim HW and Bae JM: Treatment outcomes of topical calcineurin
inhibitor therapy for patients with vitiligo: A systematic review
and Meta-analysis. JAMA Dermatol. 155:929–938. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chang HC, Hsu YP and Huang YC: The
effectiveness of topical calcineurin inhibitors compared with
topical corticosteroids in the treatment of vitiligo: A systematic
review and meta-analysis. J Am Acad Dermatol. 82:243–245.
2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ebrahim HM, Elkot R and Albalate W:
Combined microneedling with tacrolimus vs. tacrolimus monotherapy
for vitiligo treatment. J Dermatolog Treat: Feb 11, 2020 (Epub
ahead of print).
|
|
31
|
Abd-Elazim NE, Yassa HA and Mahran AM:
Microdermabrasion and topical tacrolimus: A novel combination
therapy of vitiligo. J Cosmet Dermatol. 19:1447–1455.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bikle D and Christakos S: New aspects of
vitamin D metabolism and action-addressing the skin as source and
target. Nat Rev Endocrinol. 16:234–252. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Holick MF: Vitamin D deficiency. N Engl J
Med. 357:266–281. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Slominski AT, Kim TK, Hobrath JV, Oak ASW,
Tang EKY, Tieu EW, Li W, Tuckey RC and Jetten AM: Endogenously
produced nonclassical vitamin D hydroxy-metabolites act as ‘biased’
agonists on VDR and inverse agonists on RORα and RORγ. J Steroid
Biochem Mol Biol. 173:42–56. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Slominski AT, Chaiprasongsuk A, Janjetovic
Z, Kim TK, Stefan J, Slominski RM, Hanumanthu VS, Raman C, Qayyum
S, Song Y, et al: Photoprotective properties of Vitamin D and
lumisterol hydroxyderivatives. Cell Biochem Biophys. 78:165–180.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Slominski AT, Kim TK, Takeda Y, Janjetovic
Z, Brozyna AA, Skobowiat C, Wang J, Postlethwaite A, Li W, Tuckey
RC and Jetten AM: RORα and RORγ are expressed in human skin and
serve as receptors for endogenously produced noncalcemic
20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 28:2775–2789.
2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Slominski RM, Tuckey RC, Manna PR, Jetten
AM, Postlethwaite A, Raman C and Slominski AT: Extra-adrenal
glucocorticoid biosynthesis: Implications for autoimmune and
inflammatory disorders. Genes Immun. 21:150–168. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Aranow C: Vitamin D and the immune system.
J Investig Med. 59:881–886. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chiavérini C, Passeron T and Ortonne JP:
Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol
Venereol. 16:137–138. 2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rodríguez-Martín M, García Bustínduy M,
Sáez Rodríguez M and Noda Cabrera A: Randomized, double-blind
clinical trial to evaluate the efficacy of topical tacalcitol and
sunlight exposure in the treatment of adult nonsegmental vitiligo.
Br J Dermatol. 160:409–414. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kumaran MS, Kaur I and Kumar B: Effect of
topical calcipotriol, betamethasone dipropionate and their
combination in the treatment of localized vitiligo. J Eur Acad
Dermatol Venereol. 20:269–273. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ibrahim ZA, Hassan GF, Elgendy HY and
Al-Shenawy HA: Evaluation of the efficacy of transdermal drug
delivery of calcipotriol plus betamethasone versus tacrolimus in
the treatment of vitiligo. J Cosmet Dermatol. 18:581–588.
2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Naini FF, Shooshtari AV, Ebrahimi B and
Molaei R: The effect of pseudocatalase/superoxide dismutase in the
treatment of vitiligo: A pilot study. J Res Pharm Pract. 1:77–80.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Schallreuter KU, Krüger C, Würfel BA,
Panske A and Wood JM: From basic research to the bedside: Efficacy
of topical treatment with pseudocatalase PC-KUS in 71 children with
vitiligo. Int J Dermatol. 47:743–753. 2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bakis-Petsoglou S, Le Guay JL and Wittal
R: A randomized, double-blinded, placebo-controlled trial of
pseudocatalase cream and narrowband ultraviolet B in the treatment
of vitiligo. Br J Dermatol. 161:910–917. 2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Alshiyab DM, Al-Qarqaz FA, Muhaidat JM,
Alkhader YS, Al-Sheyab RF and Jafaar SI: Comparison of the efficacy
of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical
pseudocatalase/superoxide dismutase gel in children with limited
vitiligo: A randomized controlled trial. J Dermatolog Treat: Feb
11, 2020 (Epub ahead of print).
|
|
47
|
Agarwal K, Podder I, Kassir M, Vojvodic A,
Schwartz RA, Wollina U, Valle Y, Lotti T, Rokni GR, Grabbe S and
Goldust M: Therapeutic options in vitiligo with special emphasis on
immunomodulators: A comprehensive update with review of literature.
Dermatol Ther. 33(e13215)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Tsuji T and Hamada T: Topically
administered fluorouracil in vitiligo. Arch Dermatol. 119:722–727.
1983.PubMed/NCBI
|
|
49
|
Abdelwahab M, Salah M, Samy N, Rabie A and
Farrag A: Effect of Topical 5-fluorouracil alone versus its
combination with erbium:YAG (2940 nm) laser in treatment of
vitiligo. Clin Cosmet Investig Dermatol. 13:77–85. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sethi S, Mahajan BB, Gupta RR and Ohri A:
Comparative evaluation of the therapeutic efficacy of dermabrasion,
dermabrasion combined with topical 5% 5-fluorouracil cream, and
dermabrasion combined with topical placentrex gel in localized
stable vitiligo. Int J Dermatol. 46:875–879. 2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Anbar T, Westerhof W, Abdel-Rahman A,
El-Khayyat M and El-Metwally Y: Treatment of periungual vitiligo
with erbium-YAG-laser plus 5-flurouracil: A left to right
comparative study. J Cosmet Dermatol. 5:135–139. 2006.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mohamed HA, Mohammed GF, Gomaa AH and
Eyada MM: Carbon dioxide laser plus topical 5-fluorouracil: A new
combination therapeutic modality for acral vitiligo. J Cosmet Laser
Ther. 17:216–223. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Mina M, Elgarhy L, Al-Saeid H and Ibrahim
Z: Comparison between the efficacy of microneedling combined with
5-fluorouracil vs. microneedling with tacrolimus in the treatment
of vitiligo. J Cosmet Dermatol. 17:744–751. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Abdelmaksoud A, Dave DD, Lotti T and
Vestita M: Topical methotrexate 1% gel for treatment of vitiligo: A
case report and review of the literature. Dermatol Ther.
32(e13013)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Eldelee SA, Gheida SF, Sarhan NI, Ibrahim
ZA and Elfar NN: Evaluation of the effect of combined intralesional
injection of prostaglandin F2α with narrow band UVB phototherapy in
treatment of resistant cases of vitiligo. J Dermatolog Treat: Sep
4, 2019 (Epub ahead of print).
|
|
56
|
Jha AK, Prasad S and Sinha R: Bimatoprost
ophthalmic solution in facial vitiligo. J Cosmet Dermatol.
17:437–440. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Kanokrungsee S, Pruettivorawongse D and
Rajatanavin N: Clinical outcomes of topical bimatoprost for
nonsegmental facial vitiligo: A preliminary study. J Cosmet
Dermatol. 20:812–818. 2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Nowroozpoor Dailami K, Hosseini A,
Rahmatpour Rokni G, Saeedi M, Morteza-Semnani K, Sadeghi Z,
Ghasemzadeh Diva SM, Goldust M, Lotti T, Vojvodic A, et al:
Efficacy of topical latanoprost in the treatment of eyelid
vitiligo: A randomized, double-blind clinical trial study. Dermatol
Ther. 33(e13175)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kamala Subhashini P, Sankar K, Chandrakala
K and Venkataramana V: Comparative study of efficacy and safety of
topical active fragment of basic fibroblast growth factor (B FGF)
0.1% solution V/S betamethasone valerate 0.1% ointment in the
treatment of vitiligo patients. IOSR J Dental Med Sci. 14:41–47.
2015.
|
|
60
|
Shah B, Godse K, Mahajan S, Grandhi S,
Shendkar S, Sharma A, Teli C, Pathak R and Parsad D: Efficacy and
safety of basic fibroblast growth factor (bFGF) related decapeptide
solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1%
ointment in the treatment of stable vitiligo. Dermatol Ther.
32(e13109)2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Liu LY, Strassner JP, Refat MA, Harris JE
and King BA: Repigmentation in vitiligo using the Janus kinase
inhibitor tofacitinib may require concomitant light exposure. J Am
Acad Dermatol. 77:675–682.e671. 2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Hamzavi I, Jain H, McLean D, Shapiro J,
Zeng H and Lui H: Parametric modeling of narrowband UV-B
phototherapy for vitiligo using a novel quantitative tool: The
Vitiligo Area Scoring Index. Arch Dermatol. 140:677–683.
2004.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Rothstein B, Joshipura D, Saraiya A, Abdat
R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, et al:
Treatment of vitiligo with the topical Janus kinase inhibitor
ruxolitinib. J Am Acad Dermatol. 76:1054–1060.e1. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Rosmarin D, Pandya AG, Lebwohl M, Grimes
P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, et al:
Ruxolitinib cream for treatment of vitiligo: A randomised,
controlled, phase 2 trial. Lancet. 396:110–120. 2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Mobasher P, Guerra R, Li SJ, Frangos J,
Ganesan AK and Huang V: Open-label pilot study of tofacitinib 2%
for the treatment of refractory vitiligo. Br J Dermatol.
182:1047–1049. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Kim SM, Lee HS and Hann SK: The efficacy
of low-dose oral corticosteroids in the treatment of vitiligo
patients. Int J Dermatol. 38:546–550. 1999.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Seiter S, Ugurel S, Tilgen W and Reinhold
U: Use of high-dose methylprednisolone pulse therapy in patients
with progressive and stable vitiligo. Int J Dermatol. 39:624–627.
2000.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Imamura S and Tagami H: Treatment of
vitiligo with oral corticosteroids. Dermatology. 153:179–185.
1976.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Banerjee K, Barbhuiya JN, Ghosh AP, Dey SK
and Karmakar PR: The efficacy of low-dose oral corticosteroids in
the treatment of vitiligo patient. Indian J Dermatol Venereol
Leprol. 69:135–137. 2003.PubMed/NCBI
|
|
70
|
Pasricha JS and Khaitan BK: Oral
mini-pulse therapy with betamethasone in vitiligo patients having
extensive or fast-spreading disease. Int J Dermatol. 32:753–757.
1993.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Kanwar AJ, Mahajan R and Parsad D:
Low-dose oral mini-pulse dexamethasone therapy in progressive
unstable vitiligo. J Cutan Med Surg. 17:259–268. 2013.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Radakovic-Fijan S, Fürnsinn-Friedl AM,
Hönigsmann H and Tanew A: Oral dexamethasone pulse treatment for
vitiligo. J Am Acad Dermatol. 44:814–817. 2001.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Majid I, Imran S and Batool S: Apremilast
is effective in controlling the progression of adult vitiligo: A
case series. Dermatol Ther. 32(e12923)2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Huff SB and Gottwald LD: Repigmentation of
tenacious vitiligo on apremilast. Case Rep Dermatol Med.
2017(2386234)2017.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Craiglow BG and King BA: Tofacitinib
citrate for the treatment of vitiligo: A pathogenesis-directed
therapy. JAMA Dermatol. 151:1110–1112. 2015.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Komnitski M, Komnitski A, Komnitski Junior
A and Silva de Castro CC: Partial repigmentation of vitiligo with
tofacitinib, without exposure to ultraviolet radiation. An Bras
Dermatol. 95:473–476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Scheinberg M, Ferreira SB and Santos DDCB:
Tofacitinib-induced remission simultaneously in arthritis and
vitiligo. Eur J Rheumatol. 8:55–56. 2021.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Song X, Xu A, Pan W, Wallin B, Kivlin R,
Lu S, Cao C, Bi Z and Wan Y: Minocycline protects melanocytes
against H2O2-induced cell death via JNK and p38 MAPK pathways. Int
J Mol Med. 22:9–16. 2008.PubMed/NCBI
|
|
79
|
Parsad D and Kanwar A: Oral minocycline in
the treatment of vitiligo-a preliminary study. Dermatol Ther.
23:305–307. 2010.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Singh A, Kanwar AJ, Parsad D and Mahajan
R: Randomized controlled study to evaluate the effectiveness of
dexamethasone oral minipulse therapy versus oral minocycline in
patients with active vitiligo vulgaris. Indian J Dermatol Venereol
Leprol. 80:29–35. 2014.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Njoo MD, Das PK, Bos JD and Westerhof W:
Association of the Kobner phenomenon with disease activity and
therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol.
135:407–413. 1999.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Siadat AH, Zeinali N, Iraji F,
Abtahi-Naeini B, Nilforoushzadeh MA, Jamshidi K and Khosravani P:
Narrow-band ultraviolet B versus oral minocycline in treatment of
unstable vitiligo: A prospective comparative trial. Dermatol Res
Pract. 2014(240856)2014.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Al-Kuraishy H, Hussian N, Al-Naimi M and
Al-Gareeb A: Statins role in vitiligo: A mini-review. Turkish J
Dermatol. 14:1–7. 2020.
|
|
84
|
Agarwal P, Rashighi M, Essien KI, Richmond
JM, Randall L, Pazoki-Toroudi H, Hunter CA and Harris JE:
Simvastatin prevents and reverses depigmentation in a mouse model
of vitiligo. J Invest Dermatol. 135:1080–1088. 2015.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Nguyen S, Chuah SY, Fontas E, Khemis A,
Jhingan A, Thng STG and Passeron T: Atorvastatin in combination
with narrowband UV-B in adult patients with active vitiligo: A
randomized clinical trial. JAMA Dermatol. 154:725–726.
2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Iraji F, Banihashemi SH, Faghihi G,
Shahmoradi Z, Tajmirriahi N and Jazi SB: A comparison of
betamethasone valerate 0.1% cream twice daily plus oral simvastatin
versus betamethasone valerate 0.1% Cream alone in the treatment of
vitiligo patients. Adv Biomed Res. 6(34)2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Noël M, Gagné C, Bergeron J, Jobin J and
Poirier P: Positive pleiotropic effects of HMG-CoA reductase
inhibitor on vitiligo. Lipids Health Dis. 3(7)2004.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Vanderweil SG, Amano S, Ko WC, Richmond
JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B
and Harris JE: A double-blind, placebo-controlled, phase-II
clinical trial to evaluate oral simvastatin as a treatment for
vitiligo. J Am Acad Dermatol. 76:150–151.e3. 2017.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Alghamdi K and Khurrum H: Methotrexate for
the treatment of generalized vitiligo. Saudi Pharm J. 21:423–424.
2013.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Garza-Mayers AC and Kroshinsky D: Low-dose
methotrexate for vitiligo. J Drugs Dermatol. 16:705–706.
2017.PubMed/NCBI
|
|
91
|
Nageswaramma S, Vani T and Indira N:
Efficacy of methotrexate in vitiligo. IOSR J Dental Med Sci.
17:16–19. 2018.
|
|
92
|
Singh H, Kumaran MS, Bains A and Parsad D:
A randomized comparative study of oral corticosteroid minipulse and
low-dose oral methotrexate in the treatment of unstable vitiligo.
Dermatology. 231:286–290. 2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
ElGhareeb MI, Metwalli M and AbdelMoneim
N: Combination of oral methotrexate and oral mini-pulse
dexamethasone vs. either agent alone in vitiligo treatment with
follow up by dermoscope. Dermatol Ther. 33(e13586)2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Madarkar M, Ankad B and Manjula R:
Comparative study of safety and efficacy of oral betamethasone
pulse therapy and azathioprine in vitiligo. Clin Dermatol Rev.
3:121–125. 2019.
|
|
95
|
Radmanesh M and Saedi K: The efficacy of
combined PUVA and low-dose azathioprine for early and enhanced
repigmentation in vitiligo patients. J Dermatolog Treat.
17:151–153. 2006.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Taneja A, Kumari A, Vyas K, Khare AK,
Gupta LK and Mittal AK: Cyclosporine in treatment of progressive
vitiligo: An open-label, single-arm interventional study. Indian J
Dermatol Venereol Leprol. 85:528–531. 2019.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Mutalik S, Shah S, Sidwadkar V and Khoja
M: Efficacy of cyclosporine after autologous noncultured melanocyte
transplantation in localized stable vitiligo-a pilot, open label,
comparative study. Dermatol Surg. 43:1339–1347. 2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Bishnoi A, Vinay K, Kumaran MS and Parsad
D: Oral mycophenolate mofetil as a stabilizing treatment for
progressive non-segmental vitiligo: Results from a prospective,
randomized, investigator-blinded pilot study. Arch Dermatol Res:
Jul 31, 2020 (Epub ahead of print).
|
|
99
|
Slominski AT, Zmijewski MA, Plonka PM,
Szaflarski JP and Paus R: How UV light touches the brain and
endocrine system through skin, and Why. Endocrinology.
159:1992–2007. 2018.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Skobowiat C, Postlethwaite AE and
Slominski AT: Skin exposure to ultraviolet B rapidly activates
systemic neuroendocrine and immunosuppressive responses. Photochem
Photobiol. 93:1008–1015. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Skobowiat C and Slominski AT: UVB
activates hypothalamic-pituitary-adrenal axis in C57BL/6 Mice. J
Invest Dermatol. 135:1638–1648. 2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wu CS, Yu CL, Lan CC and Yu HS:
Narrow-band ultraviolet-B stimulates proliferation and migration of
cultured melanocytes. Exp Dermatol. 13:755–763. 2004.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Mohammad TF, Al-Jamal M, Hamzavi IH,
Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG and Esmat SM: The
Vitiligo Working Group recommendations for narrowband ultraviolet B
light phototherapy treatment of vitiligo. J Am Acad Dermatol.
76:879–888. 2017.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ
and Kim GM: Phototherapy for Vitiligo: A systematic review and
Meta-analysis. JAMA Dermatol. 153:666–674. 2017.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Li R, Qiao M, Wang X, Zhao X and Sun Q:
Effect of narrow band ultraviolet B phototherapy as monotherapy or
combination therapy for vitiligo: A Meta-analysis. Photodermatol
Photoimmunol Photomed. 33:22–31. 2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Tovar-Garza A, Hinojosa JA, Hynan LS and
Pandya AG: Addition of oral minipulse dexamethasone to narrowband
ultraviolet B phototherapy and topical steroids helps arrest
disease activity in patients with vitiligo. Br J Dermatol.
180:193–194. 2019.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Phan K, Phan S, Shumack S and Gupta M:
Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with
phototherapy: Systematic review and meta-analysis. J Dermatolog
Treat: Apr 2, 2020 (Epub ahead of print).
|
|
108
|
Khemis A, Fontas E, Moulin S, Montaudié H,
Lacour JP and Passeron T: Apremilast in Combination with narrowband
UVB in the treatment of vitiligo: A 52-week monocentric prospective
randomized placebo-controlled study. J Invest Dermatol.
140:1533–1537.e2. 2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Lim HW, Grimes PE, Agbai O, Hamzavi I,
Henderson M, Haddican M, Linkner RV and Lebwohl M: Afamelanotide
and narrowband UV-B phototherapy for the treatment of vitiligo: A
randomized multicenter trial. JAMA Dermatol. 151:42–50.
2015.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Chang HC, Lin MH and Tsai HH: Efficacy of
combination therapy with fractional carbon dioxide laser and
Ultraviolet B phototherapy for vitiligo: A systematic review and
Meta-analysis. Aesthet Surg J. 40:NP46–NP50. 2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Wu CS, Lan CC, Wang LF, Chen GS and Yu HS:
Effects of psoralen plus ultraviolet A irradiation on cultured
epidermal cells in vitro and patients with vitiligo in vivo. Br J
Dermatol. 156:122–129. 2007.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Parsad D, Kanwar AJ and Kumar B:
Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy
for the treatment of vitiligo. J Eur Acad Dermatol Venereol.
20:175–177. 2006.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Bhatnagar A, Kanwar AJ, Parsad D and De D:
Psoralen and ultraviolet A and narrow-band ultraviolet B in
inducing stability in vitiligo, assessed by vitiligo disease
activity score: An open prospective comparative study. J Eur Acad
Dermatol Venereol. 21:1381–1385. 2007.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Grimes PE: Psoralen photochemotherapy for
vitiligo. Clin Dermatol. 15:921–926. 1997.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Karagaiah P, Valle Y, Sigova J, Zerbinati
N, Vojvodic P, Parsad D, Schwartz RA, Grabbe S, Goldust M and Lotti
T: Emerging drugs for the treatment of vitiligo. Expert Opin Emerg
Drugs. 25:7–24. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, Li
C and Gao T: Comparison of the 308-nm excimer laser with the 308-nm
excimer lamp in the treatment of vitiligo-a randomized bilateral
comparison study. Photodermatol Photoimmunol Photomed. 29:27–33.
2013.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Do JE, Shin JY, Kim DY, Hann SK and Oh SH:
The effect of 308nm excimer laser on segmental vitiligo: A
retrospective study of 80 patients with segmental vitiligo.
Photodermatol Photoimmunol Photomed. 27:147–151. 2011.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Lopes C, Trevisani VF and Melnik T:
Efficacy and safety of 308-nm monochromatic excimer lamp versus
other phototherapy devices for vitiligo: A systematic review with
meta-analysis. Am J Clin Dermatol. 17:23–32. 2016.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Bae JM, Hong BY, Lee JH, Lee JH and Kim
GM: The efficacy of 308-nm excimer laser/light (EL) and topical
agent combination therapy versus EL monotherapy for vitiligo: A
systematic review and meta-analysis of randomized controlled trials
(RCTs). J Am Acad Dermatol. 74:907–915. 2016.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Lotti T, Wollina U, Tchernev G, Valle Y,
Lotti J, França K, Satolli F, Rovesti M, Tirant M, Lozev I, et al:
An innovative therapeutic protocol for vitiligo: Experience with
the use of fraxel herbium laser, topical latanoprost and successive
irradiation with UVA-1 laser. Open Access Maced J Med Sci. 6:49–51.
2018.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Grimes PE and Nashawati R: Depigmentation
therapies for vitiligo. Dermatol Clin. 35:219–227. 2017.PubMed/NCBI View Article : Google Scholar
|
